In an earlier study we observed residual normal colonies in the CD34 + , lineage-negative fraction in AML with a differentiated phenotype. The phenotype of both normal and leukemic progenitors in AML M2, t(8;21) was the subject of this study. The specific translocation enabled discrimination of normal and leukemic cells. Bone marrow samples from eight patients were evaluated for CD34 and the differentiation markers CD33, CD19 and CD56. Growth in all phenotypic fractions was measured in a single cell assay, which enabled quantification of plating efficiency, colony size and determination of progenitor cell origin. No growth was observed in the CD34-negative fraction. In the CD34 
Introduction
AML is a clonal disease characterized by incomplete but also aberrant differentiation. [1] [2] [3] As in normal bone marrow leukemic stem cells are supposed to be CD34 + , lineage-negative cells, although CD34-negative stem cells have been postulated in single cases with AML. 4 In an earlier study we doublelabeled AML bone marrow cells with CD33 and CD34 and used single cell sorting and cloning from the different phenotypic fractions to establish the origin of the clonogenic cells. 5 In AML with a more 'mature' phenotype (ie with the blast cell phenotype CD34 + /CD33 + highly proliferative myeloid, erythroid and mixed colonies could be cloned exclusively from the very small CD34 + /CD33 − fraction. In a few patients with a numerical chromosomal abnormality these colonies appeared disomic when evaluated with in situ hybridization (ISH). 5 These findings suggested that by gating out the majority of differentiated CD34
+ cells residual normal progenitors were detectable in the CD34 chromosomal aberrations may be present within a (pre) leukemic subclone, disomy does not definitively prove the nonleukemic origin. A leukemic marker allows a more precise ascertainment of the presence of residual normal and leukemic progenitors in leukemic bone marrow. In this study, both residual normal and leukemic progenitors in the CD34 + , lineage-negative fraction could be evaluated in AML samples with the translocation (8;21) , characteristic for the leukemic clone. 6, 7 As a result of the t(8;21) translocation the AML-1 gene on chromosome 21 and the ETO gene on chromosome 8 are interrupted and a chimeric AML1/ETO gene on the der (8) chromosome is generated. The hybrid gene is highly expressed in t(8;21) leukemic cells and is believed to have a primary role in leukemogenesis as an aberrant transcription factor. [8] [9] [10] The AML1/ETO fusion transcript is consistently detected by RT-PCR. 11, 12 Furthermore AML with t(8;21) has a specific immunophenotype. The majority of the blast cells express CD34 and a combination of myeloid and lymphatic differentiation markers CD33, CD19 and CD56. [13] [14] [15] In this study, mononuclear cells were stained with CD34 FITC and CD33-PE, CD56-PE and CD19 PE. Single cells from the different phenotypic fractions were sorted and cloned in 96-well plates. The single cell sorting method allows analysis of the offspring of individual cells, excluding inhibitory or stimulatory effects of accessory cells. Furthermore, by single cell sorting it is possible to sort and to clone very small subpopulations. The plating efficiency in single cell assay defined as the number of wells showing growth in normal donor CD34 + cells is high, up to 60-70%. 16 Sorting and cloning the different populations in AML with t(8;21) yielded highly proliferative, myeloid, erythroid and mixed colonies in the CD34 + , lineage-negative fractions as well as leukemic colonies, which were smaller in size.
Materials and methods

AML bone marrow samples
Bone marrow aspirates were obtained from eight newly diagnosed and untreated patients with AML, with the t(8;21) translocation. Nucleated cells were isolated by Ficoll (Sigma, St Louis, MO, USA) 1.077 g/ml density centrifugation. After washing twice with glucose-phosphate buffered saline the interface cells were suspended in Iscove's medium (Flow Laboratories, Irvine, UK) with 10% (v/v) fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 15 U/ml preservative-free heparin at a cell concentration of about 40 × 10 6 cells/ml. This cell suspension was diluted 1:1 with medium containing 20% DMSO (v/v) on ice. The cells were cryopreserved (Kryo 10; PlanerBiomed, Sunbury, UK) in 2 ml freezing tubes and stored at −198°C.
Thawing and labeling of bone marrow cells
The vials were thawed rapidly in a 37°C waterbath, and the suspension diluted in FBS containing 0.02 mg/ml DNAse (deoxyribonuclease I, grade II, from bovine pancreas, Boehringer Mannheim, Mannheim, Germany and 4 M MgSO 4 and 15 U/ml preservative-free heparin. After washing, the cell pellet was incubated for 30 min at 4°C, with 100 l of monoclonal antibodies diluted in 10% pooled human serum (to reduce non-specific binding); anti-CD34-FITC 1:10, (HPCA-2; Becton Dickinson, Oxnard, CA, USA), anti-CD33-PE 1:20 (My-9; Becton Dickinson, anti-CD19-PE (HD-37; Dako, Glostrup, Denmark) and anti-CD56-PE, (Leu-19; Becton Dickinson, San Jose, CA, USA). After labeling the cells were washed once and diluted in glucose-phosphate buffer with 1% BSA.
Single cell sorting and cloning
The labeled cells were sorted through a Coulter Epics Elite flow cytometer (Coulter, Hialeah, FL, USA) equipped with an autoclone unit. Cells were excitated with a single 488 nm Argonion laser running at 15 mW. Dichroic mirrors of 550 and 625 nm and band pass filters 525/40 and 575/30 were used. A gate on the forward vs right angle light scatter diagram was used to exclude dead cells and debris. To standardize for fluorescence intensity and spectral overlap commercially available green and red fluorescent beads (Calibrite; Becton Dickinson) were used.
Single cells were sorted in round-bottom 96-well plates (Costar No. 3799, Cambridge, MA, USA), filled with 75 l liquid medium, consisting of Iscove's, penicillin 50 U/ml, streptomycin 50 g/ml (Flow Laboratories with 20% FBS, 5% deionized bovine serum albumin (BSA), 0.3 mg/ml human transferrin and 5 × 10 −5 M 2-␤-mercaptoethanol. Recombinant growth factors were added: G-CSF (20 ng/ml) and SCF (25 ng/ml), IL-3 (50 ng/ml), GM-CSF (20 ng/ml), IL-6 (10 ng/ml) and erythropoietin (1.5 U/ml) (Eprex; Cilag, Brussels, Belgium). The plates were placed in an incubator at 37°C, 5% CO 2 , in a fully humidified atmosphere.
Evaluation of growth and differentiation
The cells in each individual well were counted under an inverted microscope. Due to the round-bottom configuration of the wells, the cells sedimented and stayed in the center of the well. Counting was started at day 5 and repeated twice weekly until no further growth and differentiation were observed. Apart from the number of cells the configuration of the cells while differentiating was noted as granulocytic, monocytic, erythroid and mixtures of these. This was checked by MGM-staining of representative colonies. Cluster growth was defined as growth of 10 or more cells/well, colony growth as 50 or more cells/well. Colonies were categorized as small (50-150 cells), intermediate (150-5000 cells) and large colonies (Ͼ5000 cells).
RNA isolation
The t(8;21)-positive cell line Kasumi-1, used as a positive control in the RT-PCR, was kindly provided by Dr N Kamada. 17 Total RNA was extracted from each individual colony, from the eight AML blast samples and the Kasumi-1 cell line using the guanidinium thiocyanate acid phenol chloroform procedure 18 with minor modifications. Briefly, 100 l of guanidinium thiocyanate solution containing 100 g/ml yeast tRNA (Boehringer Mannheim) as a carrier was added to the cells, and thoroughly mixed. If RNA isolation of the colonies was performed on a later date the colonies with the GITC solution were stored at −20°C. After phenol/chloroform extraction and two isopropanol precipitations, a 75% ethanol wash was applied and RNA was dissolved in 25 l of DEPC-treated distilled water for 10 min at 65°C and subsequently the samples were stored at −80°C.
Reverse transcriptase and polymerase chain reactions (RT-PCR)
The cDNA synthesis reaction was performed in a total volume of 20 l, containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 625 M dNTPs, 5 M random hexamers (Pharmacia, Uppsala, Sweden), 20 U RNAsin (Promega, Madison, WI, USA) and 200 U Mo-MLV reverse transcriptase (Life Technologies, Gaithersburg, MD, USA). To this, 5 l of RNA or dH 2 O was added and the mixture was overlaid with 100 l mineral oil. The reaction was performed for 10 min at 20°C, followed by 42°C for 45 min and a 10 min incubation step at 95°C. The sequence of the AML 1 and ETO-primers used is shown in 5Ј to 3Ј orientation AML/ETO-3: TGC TTC TCA GTA CGA TTT CGA; AML1-5: GAA GTG GAA GAG GGA AAA GCT and the nested 821U: AGC TTC ACT CTG ACC ATC AC.
After cDNA synthesis, the total volume was increased up to 100 l containing 50 mM KCl, 20 mM Tris pH 8.4, 1.5 mM MgCl 2 , 0.001% gelatin, 30 pmol of the AML1-5 and the AML/ETO-3 primers and 2.5 U Taq polymerase (Gibco BRL, Gaithersburg, MD, USA). PCR amplification was performed in a thermocycler 480 (Perkin Elmer Cetus, Norwalk, CT, USA) starting with a denaturation step at 94°C for 5 min, followed by 30 cycles of 94°C for 1.5 min, 55°C for 2 min, 72°C for 2 min. After the last cycle, the extension phase was prolonged to 10 min. After this, the samples were cooled to 4°C. Then, 25 l of this reaction was added to 25 l containing 50 M KCl, 20 mM Tris pH 8.4, 1.5 mM MgCl 2 , 0.001% gelatin, 250 M dNTPs, 15 pmol of the 821 U and the AML/ETO-3 primers and 2.5 U Taq polymerase and used for a second round of amplification for a further 30 cycles using the 821 U and AML/ETO-3 primers. Control for the presence of amplifiable RNA was a 40 cycle ␤2 microglobulin PCR followed by a second PCR of 25 cycles with the same ␤2 microglobulin primers. In all experiments two t(8;21)-negative controls were included throughout RNA extraction, reverse transcription and PCR. A sample of 15 l of the PCR products was loaded onto 2% agarose gel and analyzed by electrophoresis and Southern blotting using standard procedures. The probe used in the blotting was ACC CAC CGC AAG TCG CCA CCT. A negative result for the AML/ETO transcript was considered as absence of leukemic cells if the control PCR proved the presence of RNA in the reaction. It is essential in this statement that the AML/ETO PCR is more sensitive than control PCR for RNA. Theoretically, leukemic cells might be negative in the reaction if they do not express the AML/ETO transcript.
Results
Immunophenotype of the AML blast cells
Bone marrow mononuclear cells of eight patients with AML t(8;21) were labeled with CD34-FITC and CD33-PE, CD19-PE and CD56-PE, respectively. CD34 labeling resulted in a rather clear separation of positive and negative cells. The percentage CD34-positive cells varied between 32 and 83% (Table 1) . CD33
+ and CD19 + cells were found in all samples, the CD33 + fraction varied from 38 to 73%, the CD19 + fraction from 31 to 52% of the nucleated cells. CD33 and CD19 fluorescence gradually increased from dull to dim and bright cells. Part of the CD33
+ and CD19 + cells may be residual myeloid and B cells, respectively. Co-expression of CD34 on these cells suggests their leukemic origin, since the percentage of normal CD34 + progenitors will be much less than 1%. All but two samples (UPN 4 and 7) expressed CD56 (28-96%) ( Table 1) , visible as a more or less distinct cluster. UPN 4 and 7 showed a low percentage of CD56 + cells, no apparent cluster and a low mean fluorescence. This labeling was considered non-specific.
The objective of the study was to detect precursors (both normal and leukemic), that we hypothesized to be CD34
+ and lineage-negative. In the search for CD34 
CD19
− CD33 − fraction varied from Ͻ0.1% up to 6.5% ( Table 2 ). The enrichment for CD34
+ cells by gating out CD34 + , lineage-positive (CD56, CD19, CD33) cells was 10-to more than 650-fold.
In vitro growth of single cells sorted from the different fractions
To analyze in vitro growth within the different phenotypic fractions a single cell assay was used. After single cell sorting and cloning from the CD34
+ /CD56 + and CD34 + /CD33 − fraction growth was limited to clusters, observed in about 65% of the plates. The plating efficiency (percentage of wells showing growth) varied between 0 and 17%. No growth at all was seen in the CD34-negative fraction (Table 3 ).
In the CD34 + /CD56 − and CD34
− fractions both cluster and colony growth was observed. One to four 96-well plates were sorted for each fraction. In the CD34 + /CD19 − fraction cluster growth was seen in six out of the eight samples. Plating efficiency varied between 0 and 4%. Two samples 
/CD19
− fraction showed somewhat less colony growth ( Table 4 ). Addition of CD33 as a negative selection marker resulted in an increased colony growth in UPN 4, 6 and 7. In six out of eight samples colonies of more than 5000 cells were cultured. The majority of these colonies were found in the CD34 (Table 4) . These large colonies appeared to contain granulocytes, macrophages, erythroid cells or mixed cellular morphology.
PCR analysis on colonies derived from single cells
A 30-cycle RT-PCR using the AML1-5 and AML1/ETO3 primer on the unsorted cells showed all eight AML-M2 samples to be positive for the translocation. 12 To evaluate the sensitivity of this assay an increasing number of cells of the Kasumi-1 cell line were sorted and evaluated by semi-nested PCR. Under these conditions a positive signal for the chimeric transcript was reached when 10 or more Kasumi-1 cells were present. Semi-nested PCR was performed on single cell-derived colonies. A total of 162 colonies were harvested, while 67 were evaluated by semi-nested PCR (Table 5) .
In all experiments negative controls were included throughout RNA extraction, reverse transcription and PCR. ␤2-microglobulin mRNA was amplified as a positive control for the presence of amplifiable RNA. PCR for ␤2-microglobulin expression was negative in three colonies of UPN 7, all were about 60 cells. The more sensitive t(8;21) PCR was positive in all these three colonies.
As summarized in Table 5 all but one of the 21 colonies of Ͼ5000 cells were negative for the chimeric transcript. From the colonies between 150 and 5000 cells the vast majority (22 out of 24) were PCR-negative. From the 19 colonies Ͻ150 cells eight were PCR-positive which proves their leukemic origin, while 11 were considered residual normal, PCR-negative colonies. Including the three PCR-positive colonies of about 60 cells in UPN 7 brings the distribution to 50/50 normal and malignant.
Discussion
This study shows for the first time colony growth of both normal and leukemic progenitors in the CD34 + , lineage-depleted fraction in AML. PCR for t(8;21) on single cell-derived colonies enabled the distinction between normal and leukemic origin. AML M2 t(8;21) has specific differentiation character- Table 1. istics, the presence of CD56 and CD19 as lymphatic markers in addition to the myeloid differentiation marker CD33. All eight patient samples were positive for CD34, CD33 and CD19, although the percentage of labeled cells varied. Six of the eight leukemic blast samples carried the CD56 marker.
Semi-nested PCR (30/30 cycles) was performed on 200 sorted cells from the different CD34 + subfractions. All subfractions were positive for the presence of the chimeric transcript when evaluated by ethidium-bromide gel-electrophoresis in combination with a specific probe. The chimeric signal appeared weaker in the CD34
− /CD33 − subfraction in both samples. This confirms the presence of leukemic cells in all CD34
+ subfractions tested, and suggests the presence of residual normal progenitors in the CD34 + , lineagenegative fraction. A combination of differentiation markers and flow cytometric gating was used to enrich, sort and grow CD34 + , lineage-negative cells. Of the 45 large colonies (Ͼ150 cells) that were evaluated by semi-nested PCR three colonies were positive for the chimeric transcript. Only one of the 21 very large colonies (Ͼ5000 cells) was positive. This implies that the vast majority of the very large colonies (Ͼ93%) originates from residual normal progenitors. We can only speculate why some of the larger colonies were positive for the leukemic marker. If one considers them false positive, technical problems with sorting and labeling or PCR contamination is most likely. On the other hand, these colonies may represent true leukemic progenitors. Of the 19 small colonies (Ͻ150 cells) eight were PCR-positive, which implicated a leukemic origin. Of interest was the finding that no colonies could be cultured from the sorted CD34 + /lineage-positive cells. This is not a general phenomenon in AML, because cluster and colony growth can be generated in all immunophenotypic fractions, both CD34
+ and CD34-negative, with large variation between individual patient samples. 5 The residual normal colonies included large, highly proliferative colonies (Ͼ5000 cells) which contained differentiated cells of all lineages. The growth of these large colonies persisted for up to 4 weeks. The leukemic progenitors were Table 4 Colony growth after single cell sorting: number of colonies/96-wells UPN CD34 Ͼ150  Ͼ5000  Ͼ50  Ͼ150  Ͼ5000  Ͼ50  Ͼ150  Ͼ5000  Ͼ50  Ͼ150  Ͼ5000  Ͻ150  Ͻ5000  Ͻ150  Ͻ5000  Ͻ150  Ͻ5000  Ͻ150  Ͻ5000   1  1  2  2  2  3  2  2  3  52  2  1  4  3  1  1  1  4  1  1  1  2  1  5  2  1  3  1  4  2  2  4  2  1  6  1  1  7  1  8  1  1   Total  2  1  1  4  3  3  6  12  5  9  9  10 smaller, usually Ͻ150 cells. The leukemic clusters ceased to proliferate and became pycnotic after 1-2 weeks. Residual normal colonies have been observed in full-blown AML bone marrow samples by other investigators. [19] [20] [21] Bernstein et al 19 separated the more differentiated and more primitive cells by labeling with CD34 and CD33. The CD34 + /CD33 − fraction in AML (in contrast with CML) produced colonies that were non-clonal using G6PD as a clonality marker. Interestingly, these authors concluded from their data that in some AML precursors are non-clonal, without speculating about residual normal colonies. Coulombel et al 20 and Iland et al 21 reported overgrowth of normal BM cells over leukemic cells in long-term bone marrow culture. Coulombel et al 20 concluded that long-term marrow culture selected in favor of residual normal progenitors. However, their data also fit with our observations that the residual normal progenitors show growth and differentiation for a longer period (up to 4 weeks) compared with the leukemic progenitors. Iland et al 21 reported similar findings. In these two papers no clear differentiation was made between normal and leukemic cells, other than morphologic and cytochemical criteria. Recent reports about transplanting human leukemic cells in SCID mice favor the presence of a leukemic stem cell in the CD34 + , lineagenegative fractions, although exceptions have been reported. 4, 22, 23 Our findings suggest that leukemic progenitors in AML t(8;21) as in normal progenitors are CD34 + , lineage-negative. After acquisition of differentiation markers the cells lose their proliferative capacity, and they can divide only a few times leading to cluster formation. Finally (part of) the cells differentiate into CD34-negative cells, with certain heterogeneity in differentiation markers. The frequency of leukemic progenitors is low, in the same range or even lower than the frequency of the residual normal highly proliferative normal progenitors. The proliferative capacity of the leukemic progenitors in vitro using a cocktail of growth factors is much lower than for their normal counterparts. Both elements may explain that chemotherapy may induce a remission, which means the preferential outgrowth of normal progenitors. In the absence of effective consolidation therapy the leukemic cells will regrow slowly and cause a relapse. In vitro studies on leukemia usually focus on the overall population, while the progenitor subpopulation, only 1 in 1000-10 000 cells may be held responsible for relapse or (drug)-resistance. Therefore, future studies should focus on the progenitor subpopulation.
